Posted on 2/17/21
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results
Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2020."Last year was . . .
Posted on 2/19/21
Citybiz Interview with Jim Rogers, CEO HealthConnect Networks and Mission Broadband
James E. Rogers, Jr. (Jim) is president of a growing family of telecommunications companies that include HealthConnect Networks
Posted on 2/17/21
Elicio Therapeutics Secures $73 Million in Series B
Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph node targeting technology, announced the successful completion
Posted on 2/17/21
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its fourth quarter and full year 2020 results and recent business . . .
Posted on 2/17/21
ImmuneID Launches with $17M Financing
ImmuneID, Inc., a precision immunology company employing a proprietary platform to identify and therapeutically target antibody interactions that drive immune diseases, announced a $17M financing led
Posted on 2/17/21
Charles River Laboratories to Acquire Cognate BioServices for $875 Million
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Cognate BioServices, Inc., a premier, cell and gene . . .
Posted on 2/17/21
Moderna Hits a Short-Term Vaccine Manufacturing Delay, Still on Track for First 100 Million Doses by End of March
Moderna (NASDAQ:MRNA) has hit a bit of a snag with the manufacturing of its COVID-19 vaccine. The company's fill-and-finish contractor, Catalent (NYSE:CTLT), is experiencing delays with . . .
Posted on 2/16/21
KalVista Pharmaceuticals Closes its Upsized Public Offering of Common Stock
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the closing of its previously announced upsized public offering of 6,181,250 shares of its . . .
Posted on 2/16/21
Pulmatrix Closes of $40 Million Registered Direct Offering
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE technology, today . . .
Posted on 2/16/21
CVS Health Reports Fourth Quarter And Full-Year 2020 Results
WOONSOCKET, R.I., Feb. 16, 2021 /PRNewswire/ -- Full Year and Fourth Quarter Highlights: Full year total revenues increased to $268.7 billion, up 4.6% compared to prior year . . .
Posted on 2/16/21
IQVIA Offers of Senior Notes
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA Holdings Inc. (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc., intends to raise €1,450,000,000 in gross proceeds . . .
Posted on 2/16/21
Centessa Pharmaceuticals Launches with $250 Million Series A Financing
Centessa Pharmaceuticals launched today as a novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs. Centessa’s asset-centric
Posted on 2/16/21
The CM Group Acquires Scientific Commercialization
The CM Group, LLC, a leading provider of information and knowledge services to the biopharmaceutical community, announces the acquisition of Scientific Commercialization, LLC
Posted on 2/16/21
Baudax Bio Reports 2020 Annual Financial Results
MALVERN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today reported its . . .
Posted on 2/16/21
Here's Why You Can't Compare Vaccine Results Between Johnson & Johnson, Pfizer, and Moderna
Johnson & Johnson (NYSE:JNJ) announced late-stage results for its COVID-19 vaccine in late January. The immediate focus was on the vaccine's efficacy, which was markedly lower . . .
Posted on 2/13/21
Road to Responsibility Holds Vaccine Clinics for Staff and Residents
Julia Barruzza, residential nurse supervisor for Road to ResponsibilityRoad to Responsibility (RTR), one of the region’s largest and most successful nonprofit organizations supporting individuals with intellectual . . .
Posted on 2/12/21
Radius Health Provides Abaloparatide Business Update
BOSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) provided a business update on the abaloparatide global business. Progress was made, and continues . . .
Posted on 2/12/21
Infinity Prices of $80 Million Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic . . .
Posted on 2/12/21
SQZ Biotech Prices of Public Offering of Common Stock
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced the pricing of its underwritten public . . .
Posted on 2/12/21
Conformis Prices of $85 Million Underwritten Offering of Common Stock
BILLERICA, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (Nasdaq: CFMS) today announced it has priced an underwritten public offering of 80,952,381 shares of its . . .
Posted on 2/12/21
Arch Therapeutics Announces $6.9 Million Private Placement
FRAMINGHAM, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH), developer of novel self-assembling wound care and biosurgical devices, today announced that it . . .
Posted on 2/12/21
Forget Moderna! This Is a More Lucrative Coronavirus Stock
In the first 10 years of Moderna's (NASDAQ:MRNA) existence, the pharmaceutical and biotechnology company didn't launch a single product onto the market. That changed last December . . .
Posted on 2/12/21
Codiak Prices of $57.8 Million Public Offering of Common Stock
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as . . .
Posted on 2/12/21
Decibel Therapeutics Prices of IPO
BOSTON, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve . . .
Posted on 2/12/21
Infinity Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI), a clinical-stage biotechnology company developing eganelisib, an oral, immuno-oncology macrophage reprogramming therapeutic candidate, which is designed to address a . . .
Boston
